DHA & Lutein and fMRI Brain Mapping in Healthy Children
NCT ID: NCT01789866
Last Updated: 2023-08-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
62 participants
OBSERVATIONAL
2012-09-30
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis:
1. Children 6 years of age consuming \< 25 mg/day DHA and \< 400 μg lutein/day will show poorer activation of brain areas on fMRI than children consuming \> 150 mg/day DHA and \> 1,200 μg/day lutein.
2. Children consuming \< 400 μg lutein/day and \> 150 mg/day DHA will also show differences in fMRI results when compared to children consuming \> 150 mg/day DHA and \> 1,200 μg/day lutein.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
N-3 Fatty Acid Requirements for Human Development
NCT00620672
Essential Fatty Acid (EFA) Nutrition 5-Year-Olds X Section
NCT01112930
Essential Fatty Acid (EFA) Nutrition 5-Year-Olds Follow-Up Study
NCT01112904
Investigating the Effects of Nutrition on the Maturation of Brain Networks Associated With Memory in Infants
NCT02457078
Fatty Acids and Executive Function Development in 7-12 Year Olds
NCT02199808
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A cross-sectional observational study of 62 school-age children in Vancouver, Canada.
Dietary intake assessment:
Children's dietary intake over the previous four weeks was estimated by interview with a parent using a Food Frequency Questionnaire. Three 24h recalls were administered, using the five-pass review technique. The children's dietary intake of DHA was quantified using nutrient analysis software (ESHA Food Processor SQL, version 10.10.0.0; ESHA Research), using Canadian foods, and checking the fatty acid composition of all foods and beverages for accuracy, modifying if necessary based on labels or laboratory analysis of the product.
Blood Markers EDTA venous blood was collected and was centrifuged to collect Red Blood Cells (RBC). RBC fatty acids were extracted and quantified by routine gas liquid chromatography. RBC-DHA to DPA (n-6) ratio was used as an indicator of DHA status.
Cognitive Measures The Kaufman Assessment Battery for Children (KABC)-II (Kaufman, 2004) was administered by one of two individuals trained in child psychometric testing. The KABC consists of several scales: (1) the Sequential Processing Scale measures short-term memory; (2) the Learning Ability Scale measures long-term storage and retrieval; \& (3) the Simultaneous Processing Scale measures visual processing. Results of these 3 scales may be combined to give a composite Mental Performance Index (MPI) score. The Delayed Recall subtest was used to evaluate long-term memory.
Statistical Analysis DHA intake and RBC-DHA:DPA were log transformed; transformed data were used in the subsequent analyses. Pearson's correlation tests were conducted to test (1) the associations between DHA intake and RBC-DHA:DPA ratio and (2) the associations between DHA intake and RBC-DHA:DPA with KABC-II domain scores.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* single birth (no multiple births)
* no major illness or surgery requiring hospitalization likely to impact the outcomes
* no metabolic, congenital or allergic disease that impact food intakes
* parents have sufficient command of English language to complete the informed consent and study documents
The specific inclusion enrollment criteria for:
Group 1: children consuming \<25 mg/day DHA and \< 400 μg/day lutein, n=24; Group 2: children consuming \>150 mg/day DHA and \>1,200 μg/day lutein, n=24; Group 3: children consuming \>150 mg/day DHA and \<400 μg/day lutein, n=10;
Exclusion Criteria
* children for whom blood, diet records or developmental tests at 5 years and 9 months of age are incomplete
* children consuming 25-150 mg/day DHA or 400-1200 μg/day lutein
* children of mothers who do not sign the informed consent
* any children having a cardiac pacemaker, aneurysm clip, cochlear implant of possible metallic foreign bodies in the eyes or other contraindication as detailed in the C\&W MRI Patient Screening Form will be excluded from this study.
69 Months
78 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yvonne Lamers
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sheila M Innis, PhD
Role: PRINCIPAL_INVESTIGATOR
Child & Family Research Institute, University of British Columbia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Child & Family Resaerch Center
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H12-01306
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.